OICC Press Progress in Biomaterials 2194-0517 11 4 (December 2022) 2022 07 29 Therapeutic applications of curcumin nanomedicine formulations in cystic fibrosis 10.1007/s40204-022-00198-3 EN Cristina Quispe Facultad de Ciencias de La Salud, Universidad Arturo Prat, Iquique, 1110939, CL Jesús Herrera-Bravo Departamento de Ciencias Básicas, Facultad de Ciencias, Universidad Santo Tomas, Bogotá, CL Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus, Universidad de La Frontera, Temuco, 4811230, CL Khushbukhat Khan Department of Healthcare Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Sector H-12, Islamabad, 44000, PK Zeeshan Javed Center for Applied Molecular Biology, University of the Punjab, Lahore, PK Prabhakar Semwal Department of Biotechnology, Graphic Era University, Dehradun, IN Uttarakhand State Council for Science and Technology, Dehradun, IN Sakshi Painuli Department of Biotechnology, Graphic Era University, Dehradun, IN Senem Kamiloglu Science and Technology Application and Research Center (BITUAM), Bursa Uludag University, Gorukle, Bursa, 16059, TR Miquel Martorell Department of Nutrition and Dietetics, Faculty of Pharmacy, and Centre for Healthy Living, University of Concepción, Concepción, 4070386, CL Daniela Calina Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, Craiova, 200349, RO Javad Sharifi-Rad Facultad de Medicina, Universidad del Azuay, Cuenca, EC Journal Article 2022 07 29 Abstract Medicinal applications of turmeric-derived curcumin have been known to mankind for long ages. Its potential in managing “cystic fibrosis” has also been evaluated. This autosomal recessive genetic disease is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) which involves an impaired secretion of chloride ions and leads to hypersecretion of thick and sticky mucus and serious complications including airway obstruction, chronic lung infection, and inflammatory reactions. This narrative review aims to highlight the available evidence for the efficacy of curcumin nanoformulations in its potential treatment of cystic fibrosis. Recent research has shown that curcumin acts on the localized mutant CFTR ion channel at the plasma membrane. Preclinical studies have also shown that curcumin nanoformulations have promising effects in the treatment of cystic fibrosis. In this context, the purpose of this narrative review is to highlight the general bioactivity of curcumin, the types of formulations and related studies, thus opening new therapeutic perspectives for CF.